NASDAQ:ANGO - AngioDynamics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.32 -0.25 (-1.28 %) (As of 05/21/2019 06:00 AM ET)Previous Close$19.57Today's Range$19.21 - $19.5452-Week Range$18.11 - $25.48Volume182,421 shsAverage Volume231,175 shsMarket Capitalization$719.01 millionP/E Ratio26.11Dividend YieldN/ABeta0.68 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York. Receive ANGO News and Ratings via Email Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ANGO Previous Symbol CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone518-795-1400Debt Debt-to-Equity Ratio0.23 Current Ratio2.68 Quick Ratio1.70Price-To-Earnings Trailing P/E Ratio26.11 Forward P/E Ratio23.28 P/E GrowthN/A Sales & Book Value Annual Sales$344.29 million Price / Sales2.09 Cash Flow$1.3615 per share Price / Cash Flow14.19 Book Value$14.74 per share Price / Book1.31Profitability EPS (Most Recent Fiscal Year)$0.74 Net Income$16.33 million Net Margins1.30% Return on Equity5.41% Return on Assets4.01%Miscellaneous Employees1,145 Outstanding Shares37,216,000Market Cap$719.01 million Next Earnings Date7/10/2019 (Estimated) OptionableOptionable AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions What is AngioDynamics' stock symbol? AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO." How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Tuesday, April, 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.03. The medical instruments supplier earned $86.34 million during the quarter, compared to the consensus estimate of $88.30 million. AngioDynamics had a net margin of 1.30% and a return on equity of 5.41%. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.23 EPS. View AngioDynamics' Earnings History. When is AngioDynamics' next earnings date? AngioDynamics is scheduled to release their next quarterly earnings announcement on Wednesday, July 10th 2019. View Earnings Estimates for AngioDynamics. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics issued an update on its FY19 earnings guidance on Thursday, April, 18th. The company provided earnings per share (EPS) guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.84. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $356.31 million. What price target have analysts set for ANGO? 2 equities research analysts have issued 12-month target prices for AngioDynamics' shares. Their forecasts range from $23.00 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $23.00 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View Analyst Price Targets for AngioDynamics. What is the consensus analysts' recommendation for AngioDynamics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics. Has AngioDynamics been receiving favorable news coverage? Media headlines about ANGO stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a news impact score of 1.5 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of AngioDynamics' key competitors? Some companies that are related to AngioDynamics include Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX) and Tactile Systems Technology (TCMD). What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Mattel (MAT), General Electric (GE), Ultra Clean (UCTT), American National BankShares (AMNB), Enterprise Bancorp (EBTC), CLEAR CHANNEL O/SH (CCO), Twitter (TWTR), US Foods (USFD), General Motors (GM) and New York Times (NYT). Who are AngioDynamics' key executives? AngioDynamics' management team includes the folowing people: Mr. James C. Clemmer, CEO, Pres & Director (Age 55)Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47) Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.65%), Dimensional Fund Advisors LP (8.37%), Victory Capital Management Inc. (7.22%), Lazard Asset Management LLC (4.30%), Janus Henderson Group PLC (3.49%) and Wells Fargo & Company MN (3.18%). Company insiders that own AngioDynamics stock include James C Clemmer, Jan Stern Reed and Michael Greiner. View Institutional Ownership Trends for AngioDynamics. Which major investors are selling AngioDynamics stock? ANGO stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, BlackRock Inc., Royce & Associates LP, Renaissance Technologies LLC, Bank of Montreal Can, Morgan Stanley, Acadian Asset Management LLC and Foundry Partners LLC. View Insider Buying and Selling for AngioDynamics. Which major investors are buying AngioDynamics stock? ANGO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Tributary Capital Management LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN, Shell Asset Management Co., Penn Capital Management Co. Inc., Penn Capital Management Co. Inc. and Geode Capital Management LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics. How do I buy shares of AngioDynamics? Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AngioDynamics' stock price today? One share of ANGO stock can currently be purchased for approximately $19.32. How big of a company is AngioDynamics? AngioDynamics has a market capitalization of $719.01 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe. What is AngioDynamics' official website? The official website for AngioDynamics is http://www.angiodynamics.com. How can I contact AngioDynamics? AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected] MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 284 (Vote Outperform)Underperform Votes: 349 (Vote Underperform)Total Votes: 633MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Investing in Growth Stocks Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.